Pipeline
ADEL-D01
ADEL-D01
Tau pT217 antibody
Target Type
phosphorylated Tau (T217)
Indication
Alzheimer’s Disease, Dementia, Tauopathy
Development stage
Diagnostic product development in progress
Related Figures and/or Summary
Increased cerebrospinal fluid pT217 levels are higher than pT181 levels and are a highly specific biomarker for detecting preclinical and advanced forms of Alzheimer’s disease.
(Alzheimers Res Ther. 2020 Mar 17;12(1):26)
Application
An antibody valuable for use in diagnostic product
Application examples: digital ELISA, electrochemiluminescence, IP-LC/MS, magnetic immunoassay, microfluidics, etc.
Competitive advantages
Higher sensitivity compared to competing antibodies
Best diagnosis starts from the best-in-class antibody
Higher sensitivity compared to competing antibodies
Development stage
Current stage
- Discovery
- Clones obtained
- Superior to competing antibodies
- Pipelines
- Discovery
- Method Development
- Method Validation
ADEL-D01
Tau-pT217
Expected filing
After completion of diagnostic development, application for KFDA or CE approval is planned.
Related papers and patents
Patents
Provisional application patent plan for antibody sequences and applications